ASP Isotopes (ASPI) Projected to Post Quarterly Earnings on Wednesday

ASP Isotopes (NASDAQ:ASPI) is expected to be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect ASP Isotopes to post earnings of ($0.09) per share and revenue of $1.30 million for the quarter.

ASP Isotopes Trading Down 1.6%

Shares of ASP Isotopes stock opened at $6.56 on Wednesday. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.55 and a quick ratio of 7.54. The firm has a fifty day moving average price of $5.00 and a 200 day moving average price of $5.42. ASP Isotopes has a 1 year low of $1.86 and a 1 year high of $9.33. The stock has a market cap of $492.41 million, a PE ratio of -10.75 and a beta of 3.40.

Insider Buying and Selling at ASP Isotopes

In other news, COO Robert Ainscow sold 66,668 shares of ASP Isotopes stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $5.62, for a total value of $374,674.16. Following the sale, the chief operating officer now owns 1,419,992 shares in the company, valued at $7,980,355.04. This trade represents a 4.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Paul Elliot Mann sold 316,666 shares of ASP Isotopes stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $5.62, for a total transaction of $1,779,662.92. Following the completion of the sale, the chief executive officer now owns 7,315,454 shares in the company, valued at approximately $41,112,851.48. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 766,667 shares of company stock valued at $4,358,502. Corporate insiders own 21.40% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.